mo:re GmbH is a technology company.
mo:re GmbH has raised $2.0M across 1 funding round.
mo:re GmbH has raised $2.0M in total across 1 funding round.
mo:re GmbH is a Hamburg-based life science startup developing the MO:BOT, an automated lab platform for 3D cell culture and downstream assays (New Approach Methodologies or NAMs).[1][2][4] It serves biotech and pharma researchers in therapeutic R&D by addressing key bottlenecks in drug development, such as poor toxicity prediction from animal models and inconsistencies in traditional 2D cell cultures, through standardized, reproducible 3D models like organoids and spheroids.[1][2][4] The platform integrates software for planning, execution, and analysis, ensuring full audit trails and regulatory-compliant reports, with recent recognition as the SLAS 2025 New Product Award winner signaling strong early momentum.[1]
Backed by investors like High-Tech Gründerfonds (HTGF) and IFB Hamburg, mo:re is scaling its team and scientific applications to establish market presence in animal-free drug testing.[2][3]
Founded in Hamburg, Germany, mo:re emerged to tackle persistent challenges in 3D cell culture, where manual processes limit scalability despite the promise of organoids for better human-relevant drug testing over animal models.[2][4] CEO Lukas Gaats leads the team, with backing from HTGF's Dr. Christian Kannemeier and IFB's Stefanie Höhn, who praised the platform's potential to standardize reproducible results globally.[2] A pivotal moment came with recent seed funding, enabling market entry, team expansion, and internal R&D to unlock further applications alongside customer collaborations.[2] Early validation includes the MO:BOT's award at SLAS 2025 and its debut at BIO International Convention 2025.[1]
mo:re rides the shift to animal-free testing driven by ethical, regulatory, and efficacy pressures—animal models fail to predict human toxicity, while 3D cultures offer mechanistic insights but lack standardization.[2][4] Timing aligns with surging demand for NAMs in pharma R&D, accelerated by EU regulations and investments in scalable biotech tools post-COVID.[2] Market forces like HTGF/IFB funding favor hardware-software hybrids that enable high-throughput organoids, influencing the ecosystem by lowering barriers for reproducible disease modeling and drug screening, potentially reducing clinical failures.[2][3][4]
mo:re is poised to redefine 3D cell culture standards, with next steps focusing on team growth, customer-driven applications, and global lab adoption via its award-winning MO:BOT.[1][2] Trends like AI-enhanced analysis, stricter NAM mandates, and organoid maturation will amplify its trajectory, evolving its influence from niche automation to essential infrastructure in precision medicine. As toxicity prediction remains a drug development chokepoint, mo:re's standardized platform positions it to drive broader reproducibility in life sciences.[4]
mo:re GmbH has raised $2.0M in total across 1 funding round.
mo:re GmbH's investors include Innovationsstarter.
mo:re GmbH has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $2.0M Seed | Innovationsstarter |